Efficacy and safety of Polatuzumab Vedotin in the real-world treatment of Chinese patients with aggressive B-cell non-Hodgkin lymphoma

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500107582

Enrollment

Unknown

Registered

2025-08-14

Start date

2025-05-25

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggressive B-cell non-Hodgkin lymphoma

Interventions

Elderly group:NA

Younger group:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years at the start of treatment; 2. Diagnosed with NHL (primarily DLBCL, but also including PMBCL, PCNSL, FL [3B], trFL, trCLL, MCL, LBCL, Burkitt lymphoma, etc.); 3. Patients who are treatment-naïve or have relapsed/refractory disease; 4. Patients who will receive Polatuzumab Vedotin treatment within 1.5 years after the initiation of this study; 5. All observed patients have signed an informed consent form for experimental treatment.

Exclusion criteria

Exclusion criteria: 1. Patients currently participating in or planning to participate in any interventional clinical trials; 2. Patients deemed by the investigators to be unsuitable for participation in this study for any other reason.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate;	—

Secondary

Measure	Time frame
Complete Response rate;Best Objective Response Rate;Progression-Free Survival;Overall Survival;Diease control rate;Duration of Response;Time to nexttreatment;Disease-free survival;Event Free Survival;	—

Countries

China

Contacts

Public ContactZhou Keshu

Henan Cancer Hospital

drzhouks77@163.com+86 136 7490 2391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026